Nasus Pharma Ltd (NSRX) Form 6-K — Jun 9, 2026
Nasus Pharma announced positive preclinical results for NS003, its intranasal powder formulation of ondansetron, showing a pharmacokinetic profile comparable to intravenous administration in animal studies. The data supports the program's potential to address breakthrough nausea and vomiting in chemotherapy and post-operative patients, a significant unmet need given that 15-20% of such patients require IV treatment due to oral therapy failure. The company also reported a favorable safety profile in toxicology studies at four times the test dose, with no adverse effects observed.
Key figures
- Breakthrough nausea rate
- 15-20%
- Ondansetron patients 2023
- 6 million
- Chemo patients annually us
- 1 million
- Ondansetron peak sales usd
- 1.5 billion
- Ondansetron prescriptions 2023
- 12 million
- Toxicology test dose multiplier
- 4x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.